Clinical trials: Viral Hepatitis B
Hepatitis B
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV
The purpose of this study is to determine safety and efficacy of 30mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in chronic HBV infected patients with HBeAg negative
- Trial name
- NCT00313274
- Testing
- Clevudine
- Where
- 30 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Bukwang Pharmaceutical
Diphtheria, Tetanus
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02858440
- Testing
- Infanrix-IPV/Hib
- Where
- 5 sites in Russia
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic hepatitisB
Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B
This is a multicenter, randomized, placebo-controlled (double-blind design) versus active-controlled (open-label design) Phase I clinical trial evaluating the efficacy and safety of TVAX-008 injection in subjects with chronic…
- Trial name
- NCT07282249
- Testing
- TVAV-008, PegIFNα2b, Placeb
- Volunteers
- 630 people
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Hepatitis B
Drug Use Investigation for HEPSERA (Adefovir) Tablet
This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.
- Trial name
- NCT01863589
- Testing
- Adefovir tablets
- Volunteers
- 436 people
- Sponsor
- GlaxoSmithKline
To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
Multicenter Performance Study of TriQuik Invitro Diagnostic Device
This prospective and historical clinical study is designed to test the performance of the Genlantis TriQuik test kit (Cassette). The primary goal is to establish the sensitivity and specificity (i.e.
- Trial name
- NCT05293821
- Testing
- TriQuik IVD
- Volunteers
- 200 people
- Sponsor
- Genlantis Diagnostics
Hepatitis B, Chronic
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B.
- Trial name
- NCT02598063
- Testing
- Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a
- Where
- 12 sites in China, Hong Kong
- Volunteers
- 255 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.
- Trial name
- NCT00042393
- Testing
- Adefovir Dipivoxil
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers.
- Trial name
- NCT03714152
- Testing
- ABI-H2158
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Bacterial Infections, Virus Diseases
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.
- Trial name
- NCT01340937
- Testing
- V419, PENTACEL™, Prevnar 13™
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Tetanus
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT06618196
- Testing
- LR20062, DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
The purpose of this study is to determine the effect of renal impairment on pharmacokinetics (PK) of BMS-914143.
- Trial name
- PK (NCT01708889)
- Testing
- BMS-914143 (Peginterferon Lambda-1a)
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects with Chronic Hepatitis B
- Trial name
- NCT04426968
- Testing
- Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg
- Where
- 12 sites in China
- Volunteers
- 96 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
- Trial name
- NCT02631096
- Testing
- ARB-001467
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Arbutus Biopharma Corporation
Chronic Hepatitis B
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B
The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
- Trial name
- NCT00857675
- Testing
- AAAA, AAPA, PAAA
- Where
- 10 sites in China
- Volunteers
- 480 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
The purpose of the study is to investigate the safety and the antiviral activity of two doses of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.5 mg.
- Trial name
- NCT01026610
- Testing
- LB80380 90 mg, LB80380 150 mg, entecavir 0.5 mg
- Where
- 10 sites in China, South Korea
- Volunteers
- 115 people
- Sponsor
- LG Life Sciences
Chronic HBV Infection
A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
This is a multicenter, randomized, double-blind, placebo-controlled, multiple-ascending dose phase Ib study of HH-003 injection, which is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05542979
- Testing
- HH-003 injection
- Where
- 11 sites in China
- Volunteers
- 68 people
- Sponsor
- Huahui Health
Hepatitis B, Chronic
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine
- Trial name
- DEFINE (NCT00410202)
- Testing
- Entecavir, Tenofovir, Adefovir
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 629 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past.
- Trial name
- NCT00487747
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 23 sites in Russia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604199
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis, Viral, Human
Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.
Little is known about the nature and extent of the disturbance in hepatic function and biliary hepatic clearance in chronic viral hepatitis, while the course of this disease, the functional implications and response to treatment…
- Trial name
- NCT00915057
- Testing
- NRL972
- Where
- 4 sites in Bulgaria, Romania
- Volunteers
- 100 people
- Sponsor
- Norgine